Background {#Sec1}
==========

Previous studies have reported compositions of serum fatty acids (s-FAs) such as saturated fatty acids (SFAs), n-6 polyunsaturated fatty acids (n-6 PUFAs), n-9 monounsaturated fatty acid (n-9 MUFA), and n-3 polyunsaturated fatty acids (n-3 PUFAs), and their correlation with serum lipids (s-LPs) in healthy young or middle-aged human subjects \[[@CR1]--[@CR5]\]. The proportion of n-6 PUFAs, as a fraction of total fatty acids, decreases with increasing age. Compositions of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) were found to be positively correlated with serum total cholesterol (T-CHO), compositions of stearic acid (StA) or oleic acid (OlA) were positively correlated with serum triglycerides (TGs), and compositions of linoleic acid (LiA) or arachidonic acid (AA) were negatively correlated with TGs \[[@CR1]\].

Further, a comparison of lipid fatty acids based on concentration basis vs composition (weight %) was reported for patients with and without coronary artery disease (CAD), concluding that serum concentrations of lipid fatty acids are more accurate reflections of changes in lipid fatty acids rather than compositions \[[@CR6]\]. Concentrations of palmitic acid (PA), StA, OlA, LiA, and AA were found to be higher, and concentrations of EPA were lower in subjects with CAD than in subjects without CAD, whereas compositions of PA and StA were higher and those of EPA and DHA were lower in subjects with CAD \[[@CR6]\]. A previous study also reported that people with higher serum levels of saturated fatty acids, n-9 MUFA, and n-6 PUFAs more frequently experienced lacunar or atherosclerotic stroke during middle age (50 to 74 years old) \[[@CR7]\]. Serum FA concentrations and compositions might thus be associated with acute ischaemic stroke (AIS). However, limited information is available regarding such parameters and their association with AIS in elderly patients. The aim of our retrospective study was to investigate s-FA concentrations, s-FA compositions, and their correlation with age, serum lipids, and ischaemic stroke subtypes in AIS elderly patients.

Methods {#Sec2}
=======

We conducted a cross-sectional study of acute ischaemic stroke patients aged 50 years or older who 1) were admitted to our institution between September 2015 and March 2017 within 24 h of first stroke onset and then 2) underwent blood evaluations of s-LPs and s-FAs at arrival. We excluded patients who used statins, supplemental n-3 PUFA, fibrates, or ezetimibe at the onset. Additionally, we excluded those with a pre-hospital modified Rankin scale (mRS) score of 3 or more or a body mass index (BMI) less than 18.5, which was defined as severe disability or underweight according to the World Health Organisation (WHO) guidelines, as we determined that possible malnutrition was not appropriate for our investigation.

Measurements {#Sec3}
------------

Serum T-CHO, TG, and HDL-cholesterol (HDL-C) were measured through enzymatic analysis using reagents manufactured by Denka Seiken. A BioMajesty 6050 (JEOL Ltd., Tokyo, Japan) was used for measurements. For this purpose, 1.0 ml of serum was used to analyse fatty acids. Serum fatty acids were analysed at the Safety studies section at BML, Inc. (Tokyo, Japan). Fatty acids were extracted according to the general technique of Bligh and Dyer using tricosanoic acid (Nu-Chek Prep, Inc., MN, USA) as an internal standard. The lipid extracts were hydrolysed and extracted with chloroform and evaporated to dryness under nitrogen. After a 30% potassium methoxide methanol solution (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was added to the residual sample, it was incubated at 100 °C for 5 min and cooled. Boron trifluoride methanol reagent was added and incubated at 100 °C for 10 min for methyl esters. The samples were extracted with hexane before analysis. These samples were analysed with a capillary GC: column (BPX70, 30 m × 0.22 mm ID, 0.25 μm film thickness; SHIMADZU GLC Ltd., Tokyo, Japan). The gas chromatograph was a GC-2010Plus (SHIMADSU Corporation, Kyoto, Japan) equipped with a flame ionisation detector. Operating conditions were as follows: the oven temperature was 50 °C for 0.5 min, and then was raised to 260 °C over 25 min and held for 5 min. Injector temperature was 240 °C, the detector temperature was 280 °C, and helium as the carrier gas was delivered at 1.09 ml/min. The identification of components was based on a comparison of retention times with those of standards (Sigma-Aldrich Japan, Inc., Tokyo, Japan; Nu-Chek Prep, Inc., MN, USA). The concentration of each sample was calculated from the internal standard ratio of the standard.

Variables {#Sec4}
---------

The following fatty acids were examined: SFAs \[lauric acid (LaA; C12:0), myristic acid (MyA; C14:0), palmitic acid (PA; C16:0), stearic acid (StA; C18:0)\], an n-9 MUFA \[oleic acid (OlA; C18:1)\], n-6 PUFAs \[linoleic acid (LiA; C18:2), di-homo-gamma-linolenic acid (DGLA; C20:3), and arachidonic acid (AA; C20:4)\] and n-3 PUFAs \[alpha-linolenic acid (AlA; C18:3), eicosapentaenoic acid (EPA; C20:5), and docosahexaenoic acid (DHA; C22:6)\]. Low-density lipoprotein (LDL)-cholesterol (LDL-C) was calculated using the Friedewald formula as follows: LDL-C = T-CHO − HDL-C − TG/5. Mean blood pressure (MBP) was calculated using the following formula: DBP + (SBP − DBP) / 3.

Evaluation {#Sec5}
----------

We evaluated concentrations of s-LPs, concentrations of s-FAs and compositions created against total fatty acids of s-FAs (in weight percent; %), and correlation coefficients of s-FA concentrations and compositions with age and s-LPs. We divided age into three groups, specifically 50--64 years as working-age after menopause in females, 65--79 years as probable life expectancy after retirement, and 80 years or older as the oldest age. We also compared concentrations and compositions (%) of s-FAs between age groups and between AIS subtypes of large-artery atherosclerosis (LAA), small-vessel occlusion (SVO; lacunar stroke), cardioembolic (CE) stroke, TIA, and patients for whom AIS subtype was not determined \[[@CR8]\].

Statistical analysis {#Sec6}
--------------------

Normally distributed continuous variables are expressed as means ± standard deviations (SDs) and an unpaired Student's t-test or analysis of variance (ANOVA) was used to compare unpaired groups. Non-normally distributed continuous variables were expressed as medians and interquartile ranges (IQRs), and a Wilcoxon rank-sum test was used to compare unpaired groups. A multiple comparison test was used to compare all possible pairs among three groups. The Pearson correlation coefficient (r) was used to measure the strength of the linear relationship between normally distributed variables, and the Spearman rank correlation coefficient (r~s~) was used to measure the strength of the relationship between non-normally distributed variables. We defined 0 ≤ \|r\| \< 0.3 or 0 ≤ \|r~s~\| \< 0.3 as no correlation, 0.3 ≤ \|r\| \< 0.5 or 0.3 ≤ \|r~s~\| \< 0.5 as a weak correlation, 0.5 ≤ \|r\| \< 0.7 or 0.5 ≤ \|r~s~\| \< 0.7 as a moderate correlation, and 0.7 ≤ \|r\| \< 0.9 or 0.7 ≤ \|r~s~\| \< 0.9 as a strong correlation. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CIs) for ischaemic stroke in LAA or SVO groups. A probability (p) value less than 0.05 was considered statistically significant. We used the JMP software program (version 15.0; SAS Institute, Cary, NC, USA) to perform statistical analyses.

Results {#Sec7}
=======

A total of 463 patients with ischaemic stroke were admitted to our stroke centre during the study period. Among them, 129 patients were excluded from our analysis because of a pre-hospital mRS scores of 3 or more, 37 were excluded with a BMI less than 18.5, 57 were excluded because they did not undergo s-FA analysis at admission, and 49 were excluded for using medication for dyslipidaemia. Finally, 191 patients met our inclusion criteria (Table [1](#Tab1){ref-type="table"}). All patients were of East Asian ethnicity and were most likely of Japanese ancestry. Regarding stroke subtype, 52 (27.2%) patients experienced LAA, 50 patients experienced SVO (lacunar stroke), 50 patients (26.2%) experienced CE stroke, five patients (2.6%) experienced TIA, and for 34 (17.8%) patients, the subtype was not determined. BMI was lower in females, concentrations of T-CHO, LDL-C, and HDL-C were higher in females, and levels of DGLA, AA, and DHA were also higher in females (Table [2](#Tab2){ref-type="table"}). Table 1All patients' characteristics*n* = 191Age (m ± SD) years74.4 ± 10.4 (min: 50, max: 104)Male gender121 (63.3%)Height (m ± SD) cm160.8 ± 9.4Body Weight (MD, IQR) kg60.0, 52.5--69.0BMI (MD, IQR) kg/m223.1, 20.7--25.1MBP (MD, IQR) mmHg115, 101--128**Ischemic StrokeLarge-artery Atherosclelosis and Small-vessel Occlusion*n*** **= 102**  Large-artery Atherosclelosis (LAA)*n* = 52  Small-vessel Occlusion (SVO)*n* = 50**Cardioembolism and Others*n*** **= 89**  Cardioembolismn = 50  TIAn = 5  not determined*n* = 34**Glucose and Lipids** BS (MD, IQR) mg/dl120, 106--149 HbA1c (MD, IQR) %5.8, 5.6--6.3 T-CHO (m ± SD) mg/dl203.4 ± 40.2 LDL-C (m ± SD) mg/dl121.2 ± 33.5 HDL-C (MD, IQR) mg/dl56.1, 45.2--69.6 TG (MD, IQR) mg/dl94.5, 68.8--134.5**Saturated Fatty Acids** lauric acid (LaA) (C12:0) (MD, IQR) μg/ml1.2, 0.7--2.3 myristic acid (MyA) (C14:0) (MD, IQR) μg/ml18.7, 13.7--27.2 palmitic acid (PA) (C16:0) (MD, IQR) μg/ml680.7, 593.6--783.1 stearic acid StA (C18:0) (MD, IQR) μg/ml203.3, 175.4--233.3 LaA (C12:0) (MD, IQR) %0.04, 0.03--0.07 MyA (C14:0) (MD, IQR) %0.64, 0.51--0.88 PA (C16:0) (m ± SD) %23.7 ± 1.5 StA (C18:0) (m ± SD) %7.0 ± 0.8**n-9 Monounsaturated Fatty Acid** oleic acid (OlA) (C18:1) (MD, IQR) μg/ml602.5, 515.8--717.4 OlA (C18:1) (m ± SD) %21.3 ± 2.5**n-6 Polyunsaturated Fatty Acids** linoleic acid (LiA) (C18:2) (MD, IQR) μg/ml795.2, 658.2--928.3 dihomogammalinolenic acid (DGLA) (C20:3) (MD, IQR) μg/ml28.1, 21.6--36.4 arachidonic acid (AA) (C20:4) (MD, IQR) μg/ml146.1, 122.1--169.9 LiA (C18:2) (m ± SD) %27.1 ± 3.4 DGLA (C20:3) (m ± SD) %0.99 ± 0.27 AA (C20:4) (m ± SD) %5.1 ± 1.1**n-3 Polyunsaturated Fatty Acids** Alpha-linolenic acid (AlA) (C18:3) (MD, IQR) μg/ml21.3, 15.9--29.3 eicosapentaenoic acid (EPA) (C20:5) (MD, IQR) μg/ml62.2, 45.7--92.5 docosahexaenoic acid (DHA) (C22:6) (m ± SD) μg/ml136.9 ± 43.2 AlA (C18:3) (MD, IQR) %0.72, 0.6--0.96 EPA (C20:5) (MD, IQR) %2.2, 1.5--3.23 DHA (C22:6) (m ± SD) %4.7 ± 1.4 EPA / AA ratio (MD, IQR)0.45, 0.32--0.6 n-6 / n-3 ratio (MD, IQR)4.25, 3.38--5.2*BMI* Body mass index, *BS* Blood sugar, *T-CHO* Total cholesterol, *TG* Triglyceride*LDL-C* Low density lipoprotein cholesterol, *HDL-C* High density lipoprotein cholesterol*m* Mean, *SD* Standard deviation, *MD* Median, *IQR* Interquartile range*min* Minimum, *max* Maximum, *MBP* Mean blood pressure%: weight percent of fatty acidsn-6: n-6 polyunsaturated fatty acidsn-3: n-3 polyunsaturated fatty acidsTable 2Comparison between gender and ischemic stroke subtypesMaleFemale*p*LAA_SVOCE_O*pn* = 121*n* = 70*n* = 102*n* = 89Age (m ± SD) years74.4 ± 10.474.4 ± 10.7ns71.86 ± 10.46**77.37 ± 9.68**0.0002BMI (MD, IQR) kg/m2**23.7, 21.6--25.2**22.3, 20.1--24.8\< 0.0522.9, 20.7--24.823.5, 20.9--25.2nsGender Male6259ns Female4030**Lipids** T-CHO (m ± SD) mg/dl194.6 ± 39.4**218.4 ± 37.3**\< 0.0001**213.9 ± 41.7**191.2 ± 34.8\< 0.0001 LDL-C (m ± SD) mg/dl113.5 ± 32.3**135.6 ± 31.1**\< 0.0001**128.4 ± 34.8**113.9 ± 30.40.0028 HDL-C (MD, IQR) mg/dl53.5, 42.9--63.6**61.8, 50.9--73.9**0.002358.5, 46.4--70.655.2, 43.7--67.9ns TG (MD, IQR) mg/dl101, 68--16387, 70.5--116.3ns**106.5, 73--166.8**85.5, 64--115.80.0054**Saturated Fatty Acids** LaA (C12:0) (MD, IQR) μg/ml1,2, 0.7--2.71,2, 0.8--2.0ns1.3, 0.7--2.61.1, 0.7--1.95ns MyA (C14:0) (MD, IQR) μg/ml17.6, 13.3--29.719.2, 14.7--25.3ns19.75, 14.48--31.917.5, 13.1--23.6ns PA (C16:0) (MD, IQR) μg/ml678.6, 592.8--829.4702.1, 595.4--756.9ns**717.15, 605.0--833.1**648.4, 577.2--724.30.0023 StA (C18:0) (MD, IQR) μg/ml195.9, 167.4--229.6211.1, 187.9--236.9ns**210.4, 183.4--240.4**193.5, 164.7--221.40.003 LaA (C12:0) (MD, IQR) %0.04, 0.03--0.080.04, 0.03--0.07ns0.04, 0.03--0.080.04, 0.025--0.07ns MyA (C14:0) (MD, IQR) %0.64, 0.495--0.9350.64, 0.568--0.768ns0.65, 0.51--0.9330.64, 0.51--0.84ns PA (C16:0) (m ± SD) %**24.05 ± 1.44**23.13 ± 1.39\< 0.000123.7 ± 1.623.7 ± 1.3ns StA (C18:0) (m ± SD) %6.89 ± 0.777.11 ± 0.75ns6.95 ± 0.796.99 ± 0.08ns**n-9 Monounsaturated Fatty Acid** OlA(C18:1) (MD, IQR) μg/ml615.4, 513.6--734.6583.0, 514.8--712.9ns**638.2, 527.8--754.5**567.5, 499.4--649.30.0086 OlA (C18:1) (m ± SD) %**21.63 ± 2.52**20.59 ± 2.300.00521.29 ± 2.4621.21 ± 2.54ns**n-6 Polyunsaturated Fatty Acids** LiA (C18:2) (MD, IQR) μg/ml782.3, 643.7--919822.4, 681.0--940.4ns**844.65, 698.7--977.48**728.5, 636.45--883.70.003 DGLA (C20:3) (MD, IQR) μg/ml26.9, 21.0--34.8**31.5, 23.6--38.2**0.018**32, 24.3--38.33**24.4, 18.9--31.15\< 0.0001 AA (C20:4) (MD, IQR) μg/ml142.2, 114.9--162.3**156.3, 136.1--175.1**0.0034**155.7, 132.53--182.18**136.3, 114.05--158.15\< 0.0001 LiA (C18:2) (m ± SD) %27.036 ± 3.427.31 ± 3.35ns27.06 ± 3.4627.22 ± 3.30ns DGLA (C20:3) (m ± SD) %0.95 ± 0.25**1.05 ± 0.29**0.0125**1.04 ± 0.28**0.93 ± 0.240.0028 AA (C20:4) (m ± SD) %4.94 ± 1.17**5.27 ± 1.00**0.04525.18 ± 1,154.92 ± 1.07ns**n-3 Polyunsaturated Fatty Acids** AlA (C18:3) (MD, IQR) μg/ml21.5, 15.3--30.920.9, 16.4--27.5ns21.7, 16.13--31.1320.8, 14.75--27.55ns EPA(C20:5) (MD, IQR) μg/ml59.3, 44.7--90.173.2, 48.6--94.1ns63, 45.68--92.8862.5, 45.25--92.85ns DHA (C22:6) (m ± SD) μg/ml130.1 ± 43.5**148.6 ± 40.4**0.0012139.3 + 4.3134.15 + 4.58ns AlA (C18:3) (MD, IQR) %0.7, 0.6--0.990.72, 0.59--0.89ns0.71, 0.59--0.990.72, 0.61--0.95ns EPA (C20:5) (MD, IQR) %2.1, 1.43--3.152.29, 1.67--3.44ns2.05, 1.41--3.152.4, 1.69--3.29ns DHA (C22:6) (m ± SD) %4.47 ± 1.32**5.00 ± 1.38**0.00944.53 ± 1.414.81 ± 1.30ns EPA / AA ratio (MD, IQR)0.45, 0.315--0.60.455, 0.343--0.6ns0.43, 0.28--0.590.48, 0.365--0.68ns n-6 / n-3 ratio (MD, IQR)4.31, 3.445--5.2954.1, 3.14--5.228ns4.355, 3.428--5.6534.16, 3.21--4.99ns*m* Mean, *SD* Standard deviation, *MD* Median, *IQR* Interquartile range, *%* Weight percent of fatty acids, *p* Probability, *BMI* Body Mass Index, *T-CHO* Total cholesterol, *TG* Triglyceride, *LDL-C* Low density lipoprotein cholesterol, *HDL-C* High density lipoprotein cholesterol, *LAA_SVO* Large-artery atherosclerosis and small-vessel occlusion, *CE_O* Cardioembolism and others, *LaA* Lauric acid, *MyA* Myristic acid, *PA* Palmitic acid, *StA* Stearic acid, *OlA* Oleic acid, *LiA* Linoleic acid, *DGLA* Dihomogammalinolenic acid, *AA* Arachidonic acid, *ALA* Alpha-linolenic acid, *EPA* Eicosapentaenoic acid, *DHA* Docosahexaenoic acid, *n-6* n-6 polyunsaturated fatty acids, *n-3* n-3 polyunsaturated fatty acids

Patients with LAA or SVO (LAA_SVO) ischaemic stroke subtypes due to arteriosclerosis were younger and had higher concentrations of T-CHO, LDL-C, TG, PA, StA, OlA, LiA, DGLA, and AA than patients with an ischaemic stroke subtype of CE or others (CE_O). However, there were no differences in BMI, sex, AlA, EPA, and DHA concentrations and no differences in s-FAs compositions, except for that of DGLA, between LAA_SVO and CE_O groups (Table [2](#Tab2){ref-type="table"}).

Serum T-CHO and TG were weakly negatively correlated with age (Table [3](#Tab3){ref-type="table"}). Serum concentrations of PA, StA, OlA, LiA, DGLA, AA, and AlA were weakly negatively correlated with age and compositions of SFAs, LiA, AA, and AlA were not correlated with age. Compositions of OlA and DGLA and the EPA/AA ratio were weakly negatively correlated with age. Compositions of EPA and DHA and the n-6/n-3 ratio were weakly positively correlated with age. Most s-FA concentrations were weakly negatively correlated with age, and most s-FA compositions had no correlations with age in our patients (Table [3](#Tab3){ref-type="table"}). Serum concentrations of StA, LiA, and AA showed positive correlations with T-CHO, concentrations of SFAs, LiA, and AlA were positively correlated with TG, and the concentration of OlA was strongly correlated with TG (r~s~ = 0.7661). In contrast, no serum FA concentrations exhibited correlations with LDL-C or HDL-C (Table [3](#Tab3){ref-type="table"}). Further, compositions of MyA and OlA showed positive correlations with TG, whereas no serum FA compositions were correlated with LDL-C or HDL-C (Table [3](#Tab3){ref-type="table"}). Table 3Correlation coefficient between serum fatty acids, serum lipids concentration and ageT-CHOTG*p*LDL-CHDL-CAgeBMI*p*CCpCCCCpCCpCCpCC**Age**−0.1998P0.0057− 0.19210.0079− 0.0322Pns−0.1229ns**BMI**−0.0914ns0.1917\< 0.01−0.0668ns−0.2742\< 0.001−0.2139\< 0.01**Saturated Fatty AcidsConcentration (μg/ml)**  LaA (C12:0)0.26220.0003**0.5601**\< 0.00010.1327ns−0.0102ns− 0.1301ns0.0677ns  MyA (C14:0)0.2896\< 0.0001**0.6532**\< 0.00010.1107ns−0.002ns− 0.1290ns0.0828ns  PA (C16:0) (MD, IQR)0.4785\< 0.0001**0.6864**\< 0.00010.19730.00640.1404ns− 0.25434E-040.1255ns  StA (C18:0)**0.5655**\< 0.00010.4816\< 0.00010.2884\< 0.00010.3454\< 0.0001−0.2854\< 0.00010.0545ns    (C12:0) + (C14:0) + (C16:0) + (C18:0)**0.5081**\< 0.0001**0.6705**\< 0.00010.2180.00250.19270.0077−0.26462E-040.1136ns**Composition (%)**  LaA (C12:0)0.1222ns0.4638\< 0.00010.0369ns−0.0648ns− 0.0757ns0.0689ns  MyA (C14:0)0.0872ns**0.5203**\< 0.0001−0..0141ns−0.1013ns−0.187ns0.0593ns  PA (C16:0)−0.0922Pns0.3202\< 0.0001−0.1631P0.0245−0.19170.008−0.0127Pns0.1436\< 0.05  StA (C18:0)0.1228Pns−0.25810.0003−0.153P0.03510.3434\< 0.0001−0.0012Pns−0.0569ns**n-9 Monounsaturated Fatty AcidConcentration (μg/ml)**  OlA (C18:1)0.3245\< 0.0001**0.7661**\< 0.00010.092ns−0.0331ns− 0.3161\< 0.00010.1873\< 0.01**Composition (%)**  OlA (C18:1)−0.1742P0.0162**0.5635**\< 0.0001−0.2482P0.0006−0.4201\< 0.0001−0.2296P0.0010.2003\< 0.01**n-6 Polyunsaturated Fatty AcidsConcentration (μg/ml)**  LiA (C18:2)**0.5459**\< 0.0001**0.5088**\< 0.00010.3348\< 0.00010.21030.0036−0.3247\< 0.00010.0708ns  DGLA (C20:3)0.4914\< 0.00010.3716\< 0.00010.3294\< 0.00010.18920.0089−0.3069\< 0.00010.0579ns  AA (C20:4)**0.6393**\< 0.00010.15610.03150.4343\< 0.00010.4003\< 0.0001− 0.22950.001− 0.0400ns    (C18:2) + (C20:3) + (C20:4)**0.6259**\< 0.00010.4824\< 0.00010.3859\< 0.00010.2789\< 0.0001−0.3422\< 0.00010.0540ns**Composition (%)**  LiA (C18:2)0.1421Pns−0.14880.04050.1592p0.02820.1023ns0.0933pns−0.0329ns  DGLA (C20:3)0.1874P0.0096−0.0154ns0.1779P0.0140.1323ns−0.1514P0.0370.0066ns  AA (C20:4)0.1300Pns−0.4858\< 0.00010.1475P0.04230.2975\< 0.00010.0589Pns−0.1795\< 0.05**n-3 Polyunsaturated Fatty AcidsConcentration (μg/ml)**  AlA (C18:3)0.22210.0021**0.6345**\< 0.00010.0813ns−0.039ns−0.21460.0030.0750ns  EPA (C20:5)0.1550.0327−0.0043ns0.14390.04760.14430.04710.1094ns−0.0071ns  DHA (C22:6)0.2727P0.00010.18440.01090.1973P0.00640.1329ns0.1089Pns−0.0822ns    (C18:3) + (C20:5) + (C22:6)0.25160.00050.19190.0080.17350.01670.1331ns0.0571ns−0.0296ns**Composition (%)**  AlA (C18:3)0.0016ns0.4610\< 0.0001−0.0506ns−0.14340.0484−0.1117ns0.0157ns  EPA (C20:5)−0.0639ns−0.25980.00030.0219ns0.0629ns0.23500.001−0.0248ns  DHA (C22:6)−0.1204Pns−0.25050.00050.0234Pns0.0084ns0.3400P\< 0.0001−0.1455\< 0.05**EPA / AA ratio**−0.1367ns−0.0847ns−0.0554ns−0.0419ns0.20940.0040.0082ns**n-6 / n-3 ratio**0.14980.03920.1226ns0.0773ns0.0251ns−0.24975E-040.0456ns*m* Mean, *SD* Standard deviation, *MD* Median, *IQR* Interquartile range, *%* Weight percent of fatty acids, *p* Probability, *BMI* Body Mass Index, *T-CHO* Total cholesterol, *TG* Triglyceride, *LDL-C* Low density lipoprotein cholesterol, *HDL-C* High density lipoprotein cholesterol, *CC* Spearman's rank correlation coefficient except superscript "P", Superscript "P" meaning Pearson's correlation coefficient, *LaA* Lauric acid, *MyA* Myristic acid, *PA* Palmitic acid, *StA* Stearic acid, *OlA* Oleic acid, *LiA* Linoleic acid, *DGLA* Dihomogammalinolenic acid, *AA* Arachidonic acid, *ALA* Alpha-linolenic acid, *EPA* Eicosapentaenoic acid, *DHA* Docosahexaenoic acid, *n-6* n-6 polyunsaturated fatty acids, *n-3* n-3 polyunsaturated fatty acids

Patients aged 50--64 years had the highest concentrations of TG, PA, StA, OlA, LiA, DGLA, and AA among the three age groups, and patients aged 80 years or older had the highest compositions of EPA (2.47%) and DHA (5.14%) (Table [4](#Tab4){ref-type="table"}). Twenty-five (78.1%) of 32 patients aged 50--64 years suffered from LAA_SVO and these 25 patients had higher concentrations of TG (MD, IQR: 173, 104--223 mg/dl), PA (777.8, 704.5--960.5 μg/ml), StA (229.4, 208.6--280.05 μg/ml), OlA (742.5, 637.45--865.85 μg/ml), LiA (896.8, 806.4--1007.75 μg/ml), DGLA (36.8, 28.9--48.35 μg/ml), and AA (172.4, 146.4--204.5 μg/ml) than the seven patients with CE_O; however, there were no differences in the compositions of EPA and DHA or the EPA/AA and n-6/n-3 ratios between LAA_SVO and CE_O groups among the 68 patients aged 80 or older (Table [5](#Tab5){ref-type="table"}). These oldest 68 patients had the highest compositions of EPA and DHA; however, there were no differences in such compositions between LAA_SVO and CE_O groups (Table [5](#Tab5){ref-type="table"}). With adjustments for age, TCHO, and TG by logistic regression analysis, AA (OR = 1.011, 95% CI, 0.999--1.012), DGLA (OR = 1.042, 95% CI, 0.998--1.089), and T-CHO (OR = 1.011, 95% CI, 0.999--1.024) were weakly associated with LAA_SVO, rather than CEO_O, although TG (OR = 1.013, 95% CI, 1.003--1.024) and age (OR = 0.961, 95% CI, 0.927--0.993) were associated with LAA_SVO, rather than CEO_O. Table 4Comparison of lipids and fatty acids with significant correlation with age among age groups50 = \< Age \< 6565 = \< Age \< 8080 = \< Age*n* = 32*n* = 91*n* = 68*p*Age (m ± SD) years57.8 ± 4.172.3 ± 4.385.2 ± 4.5**Lipids** T-CHO (m ± SD) mg/dl213.9 ± 42.9203.7 ± 41.2197.9 ± 36.9ns TG (MD, IQR) mg/dl**145.5, 65.5--217.8 ab**92, 69--134 a92, 69--116 b0.0118**Saturated Fatty Acids** LaA (C12:0) (MD, IQR) μg/ml1.65, 0.8--3.651,2, 0.7--2.41.1, 0.7--1.78ns MyA (C14:0) (MD, IQR) μg/ml21.9, 14.7--38.117.6, 13.8--27.217.5, 12.9--23.9ns PA (C16:0) (MD, IQR) μg/ml**763.9, 666.9--960.5 ac**678.8, 580.7--828.7 a647.7, 577.1--735.6 c0.001 StA (C18:0) (MD, IQR) μg/ml**222.1, 196.6--258.8 bc**207.4, 175.1--241.1 b185, 165.9--215.3 c0.001**n-9 Monounsaturated Fatty Acid** OlA (C18:1) (MD, IQR) μg/ml**718.2, 614.9--863.3 bd604.8, 515.8--723.6 ab**550.3, 494.0--644.6 ad\< 0.0001 OlA (C18:1) (m ± SD) %**22.3 ± 2.4 b**21.3 ± 2.4 a20.7 ± 2.5 ab0.0046**n-6 Polyunsaturated Fatty Acids** LiA (C18:2) (MD, IQR) μg/ml**882.4, 783.3--1003.8 d826.2, 692.9--957.4 c**697.4, 636.2--845.5 cd\< 0.0001 DGLA (C20:3) (MD, IQR) μg/ml**35.6, 26.9--46.7 ac**28.7, 21.6--36.5 a,a225.3, 19.7--31.2 a2,c0.0006 AA (C20:4) (MD, IQR) μg/ml**156.6, 144.1--198.2 ab**144.7, 122.1--169.9 a140.6, 120--162.8 b0.0168 DGLA (C20:3) (m ± SD) %1.1 ± 0.50.99 ± 0.290.96 ± 0.26ns**n-3 Polyunsaturated Fatty Acids** AlA (C18:3) (MD, IQR) μg/ml**23.1, 18.0--31.2 b23, 16.3--32.6 b2**18.4, 13.9--23.5 b,b20.0026 EPA (C20:5) (MD, IQR) %1.535, 0.843--2.71 ab**2.11, 1.54--3.15 a2.47, 1.77--3.54 b**0.0048 DHA (C22:6) (m ± SD) %3.88 ± 1.34 bd**4.58 ± 1.36 b,b25.14 ± 1.18 b2,d**\< 0.0001 EPA / AA ratio (MD, IQR)0.325, 0.185--0.525 ab**0.46, 0.34--0.6 a0.48, 0.353--0.718 b**0.0115 n-6 / n-3 ratio (MD, IQR)**4.84, 3.693--7.598 b4.36, 3.42--5.46 a**3.765, 3.00--4.595 ab0.0036*m* Mean, *SD* Standard deviation, *MD* Median, *IQR* Interquartile range, *%* Weight percent of fatty acids, *T-CHO* Total cholesterol, *TG* Triglyceride, *p* Probability, a,a2: \< 0.05, b,b2: \< 0.01, c: \< 0.001, d:\< 0.0001, *LaA* Lauric acid, *MyA* Myristic acid, *PA* Palmitic acid, *StA* Stearic acid, *OlA* Oleic acid, *LiA* Linoleic acid, *DGLA* Dihomogammalinolenic acid, *AA* Arachidonic acid, *ALA* Alpha-linolenic acid, *EPA* Eicosapentaenoic acid, *DHA* Docosahexaenoic acid, *EPA* Eicosapentaenoic acid, *AA* Arachidonic acid, *n-6* n-6 polyunsaturated fatty acids, *n-3* n-3 polyunsaturated fatty acids,Table 5Comparison of lipids and fatty acids with significant correlation between age groups and ischaemic stroke subtypesAge Groups50 = \< Age \< 65 (*n* = 32)*p*65 = \< Age \< 80 (*n* = 91)*p*80 = \< Age (*n* = 68)*p*LAA_SVO (*n* = 25) 78.1%CE_O (*n* = 7) 21.9%LAA_SVO (*n* = 48) 52.7%CE_O (*n* = 43) 47.3%LAA_SVO (*n* = 29) 42.6%CE_O (*n* = 39) 57.4%Age (m ± SD) years58.0 ± 3.957.0 ± 5.2ns71.5 ± 4.373.1 ± 4.2ns84.4 ± 4.085.7 ± 4.9ns**Lipids** T-CHO (m ± SD) mg/dl**224.2 ± 39.9**177.3 ± 33.70.0083211.3 ± 45.5195.3 ± 34.3ns**209.2 ± 36.2**189.2 ± 35.50.0269 TG (MD, IQR) mg/dl**173, 104--223**57, 48--1800.03493.5, 72.3--13490, 67--134ns100, 66.5--138.586, 70.5--107ns**Saturated Fatty Acids** LaA (C12:0) (MD, IQR) μg/ml1.8, 0.95--4.351.1, 0.3--1.70.0681,2, 0.73--2.381,2, 0.7--2.6ns1.0, 0.65--2.21.1, 0.8--1.6ns MyA (C14:0) (MD, IQR) μg/ml**23.9, 16.35--39.55**13, 11.7--22.50.042518.3, 13.73--27.7317.6, 14--27.2ns18.2, 13.0--30.9517.5, 12.4--22.1ns PA (C16:0) (MD, IQR) μg/ml**777.8, 704.5--960.5**661.6, 535.1--718.40.024679.95, 573.48--814.28674.4, 597--833.1ns**728, 586.95--776.7**621.4, 577--700.30.0153 StA (C18:0) (MD, IQR) μg/ml**229.4, 208.6--280.05**168.6, 137.3--195.90.0051209.25, 186.7--240.88201.1, 174.2--243.4ns185.6, 176.25--224.9184.3, 160.9--212.1ns**n-9 Monounsaturated Fatty Acid** OlA (C18:1) (MD, IQR) μg/ml**742.5, 637.45--865.85**601.8, 496.5--640.10.0381602.65, 516.78--716.73604.8, 506--793.4ns593.9, 499.35--692.75541.1, 491.5--618.6ns OlA (C18:1) (m ± SD) %22.1 ± 2.3723.2 ± 2.5ns21.36 ± 2.5821.26 ± 2.28ns20.51 ± 2.1920.79 ± 2.68ns**n-6 Polyunsaturated Fatty Acids** LiA (C18:2) (MD, IQR) μg/ml**896.8, 806.4--1007.75**697.5, 586.2--882.20.0213804.35, 687.48--999.63833.7, 698.4--932.7ns**777.3, 666.85--866.1**664, 619.9--728.50.0182 DGLA (C20:3) (MD, IQR) μg/ml**36.8, 28.9--48.35**22, 14.9--36.90.044831.7, 24.23--37.328.3, 18.6--36.1ns**27.4, 21.45--36**23.1, 19.6--280.0252 AA (C20:4) (MD, IQR) μg/ml**172.4, 146.4--204.5**116.4, 106.2--1610.0189147.0, 130.8--175.4144.4, 113.1--158.9ns**153, 123.85--172.25**133.1, 116.2--157.50.0401 DGLA (C20:3) (m ± SD) %1.08 ± 0.230.99 ± 0.33ns1.04 ± 0.290.93 ± 0.27ns1.03 ± 0.310.91 ± 0.20ns**n-3 Polyunsaturated Fatty Acids** AlA (C18:3) (MD, IQR) μg/ml23.3, 19.05--31.421.8, 13.7--26.3ns21.7, 15.3--32.9324, 16.4--32.5ns19.0, 14.15--25.4517.3, 13.3--22.4ns EPA (C20:5) (MD, IQR) %1.43, 0.965--2.8451.93, 0.61--2.74ns2.055, 1.50--2.8352.22, 1.65--3.26ns2.23, 1.595--3.8452.54, 1.92--3.37ns DHA (C22:6) (m ± SD) %3.956 ± 1.35 b3.60 ± 1.36 abns4.515 ± 1.4584.64 ± 1.26ns5.05 ± 1.195.21 ± 1.18ns EPA / AA ratio (MD, IQR)0.32, 0.19--0.530.35, 0.15--0.54ns0.455, 0.325--0.5780.46, 0.37--0.67ns0.43, 0.305--0.7250.48, 0.38--0.7ns n-6 / n-3 ratio (MD, IQR)4.72, 3.625--7.2555.11, 3.97--7.81ns4.49, 3.448--5.6254.3, 3.38--5.18ns4.03, 3.045--4.983.73, 2.91--4.55ns*m* Mean, *SD* Standard deviation, *MD* Median, *IQR* Interquartile range, *%* Weight percent of fatty acids, *p* Probability, *T-CHO* Total cholesterol, *TG* Triglyceride, *LAA_SVO* Large-artery atherosclerosis and small-vessel occlusion, *CE_O* Cardioembolism and others, *LaA* Lauric acid, *MyA* Myristic acid, *PA* Palmitic acid, *StA* Stearic acid, *OlA* Oleic acid, *LiA* Linoleic acid, *DGLA* Dihomogammalinolenic acid, *AA* Arachidonic acid, *ALA* Alpha-linolenic acid, *EPA* Eicosapentaenoic acid, *DHA* Docosahexaenoic acid, *n-6* n-6 polyunsaturated fatty acids, *n-3* n-3 polyunsaturated fatty acids

Discussion {#Sec8}
==========

Our results of elderly AIS patients demonstrated that concentrations, but not compositions, of PA, OlA, and LiA are significantly correlated with age, TG, and ischaemic stroke subtypes. Patients with LAA_SVO were younger and had higher concentrations of T-CHO, TG, PA, StA, OlA, LiA, DGLA, and AA among patients aged 50 years or older, whereas there were no differences in the compositions of s-FAs, except for that of DGLA, between LAA_SVO and CE_O groups. Although no fatty acid concentrations were significant independent predictors of LAA_SVO, as compared to the predictive power of CE_O, AA and DGLA concentrations had a weak association with LAA_SVO rather than CE_O. Compositions of EPA and DHA were not related to ischaemic stroke subtype but rather were associated with age at onset.

A previous study reported that TG concentration had a stronger relationship with n-6 PUFA than T-CHO concentration in healthy Japanese individuals with normal serum T-CHO and TG levels, and that correlation coefficient between TG and n-6 PUFA was negative, specifically, − 0.417 in men and − 0.330 in women \[[@CR1]\]. In our elderly patients, the Spearman rank correlation coefficient comparing TG and LiA was positive, specifically 0.5088 at AIS onset. Correlations between TG and n-6 PUFA were quite different between young, healthy individuals. and elderly patients at AIS onset. A previous study reported that serum palmitic and oleic acid were associated with an increased incidence of incidental atherothrombotic, lacunar, and ischemic strokes of undetermined cause compared to that with matched controls, and that DHA and arachidonic acid were associated with a decreased incidence of ischaemic stroke \[[@CR9]\]. However, that was a case-control study in which fasting blood samples were collected from all observational study participants, and their values of serum fatty acids were not reported at AIS onset \[[@CR9]\]. Concentrations of PA, StA, and OlA were higher in the LAA_SVO group than in the CE_O group in our elderly AIS patient cohort, although patients with CE_O were not the matched controls but were ischaemic stroke patients.

A previous study reported that higher concentrations of serum n-6 PUFAs and lower levels of MUFAs are strongly associated with lower TG levels \[[@CR4]\]. However, in our study, higher concentrations of n-6 PUFAs were associated with higher TG levels. A previous study also reported that mean compositions of PA, OlA, LiA, EPA, and DHA in healthy Japanese male subjects aged 50 to 59 years were 25, 21.3, 27.3, 2.4, and 4.0%, respectively \[[@CR1]\], which were almost the same as those in our male patients (Table [2](#Tab2){ref-type="table"}). A previous study reported that the mean concentration of LiA was 2233.8 μmol/L (626.5 μg/ml) in healthy young adults in their 20s \[[@CR10]\], which was almost the same as the concentration detected in our patients. In contrast, a previous study reported that in US patients with CAD at an average age of 47 ± 5 years, the mean concentrations of PA, StA, OlA, LiA, DGLA, AA, EPA, and DHA were 823, 13, 1336, 4358, 33, 688, 67, and 40 μg/ml, respectively, and the mean compositions of PA, StA, OlA, LiA, DGLA, AA, EPA, and DHA were 11.3, 0.2, 18.4, 58.6, 0.4, 9.4, 0.9, and 0.5%, respectively \[[@CR6]\]. Their concentrations of OlA, LiA, and AA and compositions of LiA and AA were much higher, but compositions of OlA, EPA, and DHA were much lower, than those in our patients (Table [1](#Tab1){ref-type="table"}). Compared to those in our patients, concentrations of 4358 μg/ml of LiA and 688 μg/ml of AA were extremely high, and in that previous study, atherosclerotic CAD typically occurred in patients in their 40s. Our patients with LAA_SVO due to arteriosclerosis were younger among the cohort, and they also had higher concentrations of LiA and AA. Even though the concentration of a fatty acids might be high, its proportion could be low because the proportion is relative. If the concentration of one variable increases, the composition of the other variables has to decrease. Composition, therefore, is not appropriate to identify driving factors. Further, serum concentrations of fatty acids can be more easily interpreted in metabolic and therapeutic terms, as reported previously. Our study was retrospective and cross-sectional, and there was no control group. Therefore, it was not determined whether s-FA concentrations in patients with LAA_SVO were high or whether compositions of EPA and DHA were high or low, compared to those in hypothetical control subjects.

Previous studies have reported that n-3 PUFA might reduce the incidence of CAD or stroke or the mortality associated with cardiovascular disease \[[@CR11]--[@CR15]\]. The administration of highly-purified EPA appeared to reduce the risk of recurrent stroke in a Japanese population of hypercholesterolemic patients receiving low-dose statin therapy \[[@CR13]\]. In contrast, SFAs might increase the risk factors associated with these conditions \[[@CR16]\]. A fish diet decreases very-low-density lipoprotein (VLDL) but increases both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in healthy human subjects \[[@CR3]\]. Further, dietary SFAs were found to increase serum T-CHO, and it was shown that dietary n-6 PUFAs lower serum T-CHO \[[@CR17], [@CR18]\]. LiA-rich food can also lower T-CHO \[[@CR5]\]. However, in our patients, the concentration of LiA was strongly positively correlated with T-CHO and TG levels. Dietary fatty acids with lower amounts of PA, StA, OlA, and n-6 PUFAs and higher compositions of EPA and DHA might also reduce the incidence of ischaemic stroke associated with LAA_SVO and in the oldest age group, although the appropriate dietary intake of fatty acids to prevent ischaemic stroke cannot be confirmed based on the results of our study. Serum fatty acids at AIS onset are significantly influenced by recent dietary intake, and it is important to assess what types and quantities of meats and fish were consumed and what kind and volume of vegetable oils were used a few days before AIS onset. The assessment of dietary intake might lead to a recommendation for the appropriate dietary intake of fatty acids to prevent ischaemic stroke. If the appropriate intake of fatty acids is identified, a prospective randomised control study is required to address this.

Conclusions {#Sec9}
===========

In AIS elderly patients, concentrations, rather than compositions, of PA, OlA, and LiA correlated with age, TG, and ischaemic stroke subtype. Further, patients with LAA_SVO were younger and had higher concentrations of PA, OlA, and LiA than those with CE_O, although serum fatty acids were not independent predictors of LAA_SVO, as compared to the predictive power of CE_O. There were no differences in s-FA compositions between LAA_SVO and CE_O groups. Higher compositions of EPA and DHA were associated with the oldest age. Further studies are warranted to determine the appropriate dietary intake of fatty acids for AIS prevention and long life.
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